The Need for Capacity Building in Human Resource Management Related Issues: A Case Study from the Middle East (Lebanon)

YesThe remarkable evolution in the twentieth century has been a result of a new perspective in understanding the importance of investing in individuals and organizational human resources, and the implementation of capacity building strategies in various organizations and in societies. This paper explores the case of ICO, an international consultancy organization, based in the Middle East, specialized in architecture, engineering, planning, environment and economics. This qualitative study, using thirteen selected semi-structured interviews, observations, and secondary data, has been conducted in the Beirut design office of the organization. The paper aims to examine major human resource related capacity building themes in ICO which include employee involvement and motivation, recruitment and selection, in addition to performance appraisal and reward management

How might partner selection be improved by corporates to address material sustainability issues? A case study of Northumbrian Water Ltd.

Appropriate partner selection is a crucial concern for businesses who want to address material sustainability issues through cross-sector partnerships. However, the current research on materiality analysis and partner selection is still in the nascent stage of development. This paper contributes to understanding partner selection by corporates through an in-depth exploration of the business's selection of nonprofit organisation (NPO) partners, based on case study research of Northumbrian Water Ltd. (NWL), a UK private sector organisation providing water supply and sewerage services. Using the evidence from this study, we propose a framework for the selection of partners based on the prospective impact of cross-sector partnerships on material sustainability issues. Our paper also provides a useful toolkit for businesses to evaluate these prospective impacts. The framework demonstrates how materiality with respect to sustainability issues can be assessed both reactively and proactively, and how this assessment can better inform the partner selection process by corporates. This understanding of how materiality is assessed and partners are selected in practice is supported by a context specific exemplar and contributes to knowledge and practice of materiality analysis as well as cross-sector partnerships

Assessment of the quality of life of patients with lung cancer using the Medical Outcomes Study 36-item Short-Form Health Survey

OBJECTIVE: To assess the quality of life of patients with lung cancer and to compare it with that of individuals without cancer. METHODS: The Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) was administered to 57 patients diagnosed with lung cancer, treated at the Lung Cancer Outpatient Clinic of the Hospital São Paulo, and to a control group of 57 individuals recruited from the Extra Penha workout group. The Mann-Whitney test was used to compare the groups, domain by domain. The first model of logistic regression was adjusted for male gender, nonsurgical treatment, Karnofsky performance status and smoking, which were included as predictors. The second model was adjusted for each SF-36 domain in order to identify increases in the proportions of patients in stage IIIB or IV. RESULTS: The lung cancer group and the control group presented the following mean scores, respectively, for the SF-36 domains: role limitations due to physical health problems, 29.39 ± 36.94 and 82.89 ± 28.80; role limitations due to emotional problems, 42.78 ± 44.78 and 86.55 ± 28.77; physical function, 56.49 ± 28.39 and 89.00 ± 13.80; vitality, 61.61 ± 23.82 and 79.12 ± 17.68; bodily pain, 62.72 ± 28.72 and 81.54 ± 19.07; general health, 62.51 ± 25.57 and 84.47 ± 13.47; emotional well-being, 68.28 ± 23.46 and 82.63 ± 17.44; and social functioning, 72.87 ± 29.20 and 91.67 ± 17.44. The logistic regression model showed that role limitations due to physical health problems, physical function and emotional well-being were predictors of stages IIIB and IV. CONCLUSIONS: The patients with lung cancer had a poorer quality of life, especially regarding physical aspects, than did the control subjects.OBJETIVO: Avaliar a qualidade de vida de pacientes com câncer de pulmão e compará-la com a qualidade de vida de indivíduos sem câncer. MÉTODOS: O questionário Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) foi aplicado em 57 pacientes com diagnóstico de câncer de pulmão provenientes do Ambulatório de Oncopneumologia do Hospital São Paulo e em um grupo controle de 57 indivíduos participantes do Grupo de Ginástica Extra Penha. O teste de Mann-Whitney foi utilizado para comparar cada domínio entre os grupos. O primeiro modelo de regressão logística foi ajustado para sexo masculino, tratamento não cirúrgico, índice de Karnofsky e tabagismo, que foram incluídos como preditores. O segundo modelo foi ajustado para cada domínio do SF-36 para identificar aumento na proporção de estádios IIIB e IV. RESULTADOS: O grupo com câncer de pulmão e o grupo controle apresentaram, respectivamente, as seguintes pontuações médias para os domínios do SF-36: aspectos físicos, 29,39 ± 36,94 e 82,89 ± 28,80; aspectos emocionais, 42,78 ± 44,78 e 86,55 ± 28,77; capacidade funcional, 56,49 ± 28,39 e 89,00 ± 13,80; vitalidade, 61,61 ± 23,82 e 79,12 ± 17,68; dor, 62,72 ± 28,72 e 81,54 ± 19,07; estado geral de saúde, 62,51 ± 25,57 e 84,47 ± 13,47; saúde mental, 68,28 ± 23,46 e 82,63 ± 17,44; e aspectos sociais, 72,87 ± 29,20 e 91,67 ± 17,44. O modelo de regressão logística demonstrou que aspectos físicos, capacidade funcional e saúde mental foram preditores de estádios IIIB e IV. CONCLUSÕES: Os pacientes com câncer de pulmão apresentaram pior qualidade de vida em relação ao grupo controle, principalmente em relação aos aspectos físicos.Universidade Federal de São Paulo (UNIFESP)Centro Universitário São CamiloUNIFESPSciEL

Análisis de requerimientos y estudio del proceso de cocción en una fábrica de arepas

En el siguiente documento se describe el análisis realizado al proceso de cocción en una fabrica de arepas, además de la planificación y el diseño de una maquina que realizara dicho proceso. Inicialmente se establece un cronograma en el cual se determinan las actividades a llevar a cabo, las cuales se presentan a continuación: - Visita a la fabrica: Con el fin de llevar a cabo un análisis, sobre las variables que intervienen en el sistema se efectúa una visita a la fabrica, logrando establecer los principales parámetros para tener en cuenta a la hora del diseño. - Investigación: Se ejecuta una investigación sobre los principales trabajos a nivel nacional e internacional que brinden una solución automatizada al proceso de cocción de temperatura o en su defecto que establezcan una forma de realizar un control sobre las variables que intervienen en el sistema. También se indaga sobre los principales aspectos mecánicos a tener en cuenta a la hora de elaborar el diseño, tal como las características de los materiales, los costos entre otros. - Diseño: Una vez obtenido una gran cantidad de información sobre los aspectos electrónicos y mecánicos mas relevantes se procede a desarrollar un prototipo que ilustra el proceso de cocción de arepas, apoyados por el software de diseño mecánico INVENTOR 2011. - Pruebas: Se realizan una serie de pruebas con el fin de garantizar que las características del producto con el cual se esta trabajando no sean alteradas y se realizan las correcciones pertinente

Análisis de requerimientos y estudio del proceso de cocción en una fábrica de arepas

En el siguiente documento se describe el análisis realizado al proceso de cocción en una fabrica de arepas, además de la planificación y el diseño de una maquina que realizara dicho proceso. Inicialmente se establece un cronograma en el cual se determinan las actividades a llevar a cabo, las cuales se presentan a continuación: - Visita a la fabrica: Con el fin de llevar a cabo un análisis, sobre las variables que intervienen en el sistema se efectúa una visita a la fabrica, logrando establecer los principales parámetros para tener en cuenta a la hora del diseño. - Investigación: Se ejecuta una investigación sobre los principales trabajos a nivel nacional e internacional que brinden una solución automatizada al proceso de cocción de temperatura o en su defecto que establezcan una forma de realizar un control sobre las variables que intervienen en el sistema. También se indaga sobre los principales aspectos mecánicos a tener en cuenta a la hora de elaborar el diseño, tal como las características de los materiales, los costos entre otros. - Diseño: Una vez obtenido una gran cantidad de información sobre los aspectos electrónicos y mecánicos mas relevantes se procede a desarrollar un prototipo que ilustra el proceso de cocción de arepas, apoyados por el software de diseño mecánico INVENTOR 2011. - Pruebas: Se realizan una serie de pruebas con el fin de garantizar que las características del producto con el cual se esta trabajando no sean alteradas y se realizan las correcciones pertinente

Adenylate Cyclase Toxin Promotes Internalisation of Integrins and Raft Components and Decreases Macrophage Adhesion Capacity

Bordetella pertussis, the bacterium that causes whooping cough, secretes an adenylate cyclase toxin (ACT) that must be post-translationally palmitoylated in the bacterium cytosol to be active. The toxin targets phagocytes expressing the CD11b/CD18 integrin receptor. It delivers a catalytic adenylate cyclase domain into the target cell cytosol producing a rapid increase of intracellular cAMP concentration that suppresses bactericidal functions of the phagocyte. ACT also induces calcium fluxes into target cells. Biochemical, biophysical and cell biology approaches have been applied here to show evidence that ACT and integrin molecules, along with other raft components, are rapidly internalized by the macrophages in a toxin-induced calcium rise-dependent process. The toxin-triggered internalisation events occur through two different routes of entry, chlorpromazine-sensitive receptor-mediated endocytosis and clathrin-independent internalisation, maybe acting in parallel. ACT locates into raft-like domains, and is internalised, also in cells devoid of receptor. Altogether our results suggest that adenylate cyclase toxin, and maybe other homologous pathogenic toxins from the RTX (Repeats in Toxin) family to which ACT belongs, may be endowed with an intrinsic capacity to, directly and efficiently, insert into raft-like domains, promoting there its multiple activities. One direct consequence of the integrin removal from the cell surface of the macrophages is the hampering of their adhesion ability, a fundamental property in the immune response of the leukocytes that could be instrumental in the pathogenesis of Bordetella pertussis

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)